2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2689

Comparison of the 2016 ACR/EULAR and the 2002 AECG Classification Criteria in a Cohort of Patients with Suspected Primary SjöGren’s Syndrome
Abstract Number: 2802

Comparison of the Clinical, Serological, and Prognostic Differences Among Juvenile-, Adult-, and Late-Onset Lupus Nephritis in Korean Patients: A Case-Control Study
Abstract Number: 1372

Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis
Abstract Number: 1384

Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus
Abstract Number: 949

Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Abstract Number: 1929

Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype
Abstract Number: 2589

Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2175

Comparisons of Patients Prescribed Biosimilars or BIO-Originators for Autoimmune Diseases in Germany
Abstract Number: 2094

Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Abstract Number: 511

Complement C3 and C4 Levels and Its Correlation with Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 751

Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Abstract Number: 925

Complement C5a Receptor Is the Key Initiator of Neutrophil Adhesion and Inflammation in Immune Complex-Induced Arthritis
Abstract Number: 786

Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Abstract Number: 3119

Complete Whole Genome Transcriptome, DNA Methylation, and Histone Mark Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Reveals a Distinctive Epigenetic Landscape and Critical Pathogenic Pathways
Abstract Number: 1723

Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].